These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25084203)

  • 1. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
    Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
    Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
    Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
    Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of race on the CYP3A-mediated metabolism of vincristine in pediatric patients with acute lymphoblastic leukemia.
    Sims RP
    J Oncol Pharm Pract; 2016 Feb; 22(1):76-81. PubMed ID: 25305360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
    Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
    J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
    Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
    Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy.
    Marangoni-Iglecias L; Rojo-Tolosa S; Márquez-Pete N; Cura Y; Moreno-Toro N; Membrive-Jiménez C; Sánchez-Martin A; Pérez-Ramírez C; Jiménez-Morales A
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity.
    Guilhaumou R; Solas C; Bourgarel-Rey V; Quaranta S; Rome A; Simon N; Lacarelle B; Andre N
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1633-8. PubMed ID: 21968951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy.
    Nakagawa J; Takahata T; Chen Y; Saito K; Kamata K; Tachita T; Yamashita S; Saito K; Ueno K; Sato A; Sakuraba H; Niioka T
    Cancer Chemother Pharmacol; 2023 Nov; 92(5):391-398. PubMed ID: 37610625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
    Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
    JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
    Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
    Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
    Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 genotype and its impact on vincristine pharmacokinetics and development of neuropathy in Kenyan children with cancer.
    Skiles JL; Chiang C; Li CH; Martin S; Smith EL; Olbara G; Jones DR; Vik TA; Mostert S; Abbink F; Kaspers GJ; Li L; Njuguna F; Sajdyk TJ; Renbarger JL
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29115708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia.
    McClain CA; Bernhardt MB; Berger A; Bernini JC; Marquez-Do D; Winslow R; Scheurer ME; Schafer ES
    Br J Haematol; 2018 Jun; 181(5):684-687. PubMed ID: 28419449
    [No Abstract]   [Full Text] [Related]  

  • 15. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
    Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
    J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing.
    Abaji R; Ceppi F; Patel S; Gagné V; Xu CJ; Spinella JF; Colombini A; Parasole R; Buldini B; Basso G; Conter V; Cazzaniga G; Leclerc JM; Laverdière C; Sinnett D; Krajinovic M
    Pharmacogenomics; 2018 Oct; 19(15):1181-1193. PubMed ID: 30191766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine.
    Diouf B; Wing C; Panetta JC; Eddins D; Lin W; Yang W; Fan Y; Pei D; Cheng C; Delaney SM; Zhang W; Bonten EJ; Crews KR; Paugh SW; Li L; Freeman BB; Autry RJ; Beard JA; Ferguson DC; Janke LJ; Ness KK; Chen T; Zakharenko SS; Jeha S; Pui CH; Relling MV; Eileen Dolan M; Evans WE
    Clin Transl Sci; 2021 Jul; 14(4):1490-1504. PubMed ID: 33742760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular vincristine levels in lymphoblasts affect treatment outcome in childhood B-lymphoblastic leukaemia: Ma-Spore ALL 2010 study.
    Jiang N; Wang L; Xiang X; Li Z; Chiew EKH; Koo YM; Lee HS; Lin HP; Tan AM; Quah TC; Kham SKY; Goh BC; Ariffin H; Yeoh AE
    Br J Clin Pharmacol; 2021 Apr; 87(4):1990-1999. PubMed ID: 33037681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of C3435T, C1236T and C4125A Polymorphisms of the MDR-1 Gene in Egyptian Children with Acute Lymphoblastic Leukaemia.
    Talaat RM; Y K El-Kelliny M; El-Akhras BA; Bakry RM; Riad KF; Guirgis AA
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2535-2543. PubMed ID: 30256048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of polymorphisms in the drug transporter, ABCB1 on the toxicity of glucocorticoids in Saudi children with acute lymphoblastic leukaemia.
    ElFayoumi RI; Hagras MM; Abozenadaha A; Gari M; Abosoudah I; Shinawi T; Mirza T; Bawazir W
    Pharmacol Rep; 2019 Feb; 71(1):90-95. PubMed ID: 30508724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.